Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAge Labs, Inc.BIOA · Entity 5569 | Director · Chief Executive Officer | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAge Labs, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2036-02-16 | Direct | 330,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 330,000 · Balance 330,000 F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 19, 2026 16:36 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 330,000 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0002032751-26-000010 · form4-02192026_090238.xml · derivative · entry 1 Fortney Kristen · CIK 0002032751 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 16:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 233,107 | $18.12 | $4,223,036.34 |
DisclosureSEC source: 0002032751-26-000003 · form4-01152026_090111.xml · nonDerivative · entry 1 Fortney Kristen · CIK 0002032751 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 976,949 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.385 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:17 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 530,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-004857 · form4-02202025_090259.xml · derivative · entry 1 Fortney Kristen · CIK 0002032751 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,000 Underlying: Common Stock · 530,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 16:25 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 424,827 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024045 · form4-09272024_080922.xml · derivative · entry 1 Fortney Kristen · CIK 0002032751 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,827 Underlying: Common Stock · 424,827 shares Expires 2034-09-24 F1 · derivative.exercise_date: The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 25, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| April 17, 2024 Filed Sep 27, 2024 16:25 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 708,044 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001415889-24-024045 · form4-09272024_080922.xml · derivative · entry 2 Fortney Kristen · CIK 0002032751 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,044 Underlying: Common Stock · 708,044 shares Expires 2034-04-16 F2 · date: This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.